

Short Review of Metabolic Syndrome

Ritu Devi¹, Sunita Manhas², Suvarna Prasad³, Shubhangi Sharma¹,
Neeru Bhaskar⁴, Shikha Mahajan²

¹MSc. Student, ²Assistant Professor, ³Professor & Head, ⁴Professor,
Department of Biochemistry, MMIMSR, Maharishi Markandeshwar University, Ambala.

Corresponding Author: Ritu Devi

ABSTRACT

Metabolic syndrome is a group of disorders, interconnected factors that increase the risk of cardiovascular disease and type 2 diabetes mellitus. It includes high blood pressure (hypertension), large line waistline (central obesity), dyslipidemia (increase triglyceride and low level of high density lipoprotein) and increase level of fasting blood glucose. The insulin resistance plays a paramount role in connecting the different components of metabolic syndrome and adding to the syndrome's development. In addition increase free fatty acids, increase oxidative stress and alteration in adipokine profile in patients of metabolic syndrome.

Key words: Metabolic syndrome, obesity, diabetes, hypertension

INTRODUCTION

Metabolic syndrome refers to clustering of risk factors that promote the development of atherosclerotic cardiovascular disease and its clinical role is to identify individuals at risk of this combination. [1] The metabolic syndrome has been called by several other names including Syndrome X, Dysmetabolic syndrome X, Insulin Resistance Syndrome, Reaven Syndrome and the Metabolic Cardiovascular Syndrome, Obesity, Insulin Resistance, Dyslipidemia and Hypertensions are common to all. [2] The combination of central obesity, hyperglycemia, dyslipidemia and arterial hypertension characterize the so-called Metabolic Syndrome (MS). [3] While the pathogenesis of the metabolic syndrome and each of its components is complex and not well understood, central obesity and insulin resistance are acknowledged as important causative factors. Central (abdominal)

obesity, can be easily assessed using waist circumference and is independently associated with each of the other metabolic syndrome components including insulin resistance, is a prerequisite risk factor for the diagnosis of the syndrome in the new definition. Insulin resistance, which is difficult to measure in day to-day clinical practice, is not an essential requirement. [3]

HISTORY

Interestingly, a description of the Metabolic Syndrome, a condition associating hyperglycemia, hypertension and gout, was published by Kylin, a Swedish physician, in 1923. Insulin insensitivity as a feature of what we now call type 2 diabetes was brought to attention in 1936, when the term insulin-resistant was used to describe patients who required very high insulin doses. [4] In 1984, Jarrett suggested that atherosclerosis and type 2 diabetes develop as a result of a shared

antecedent and this was developed by Stern in 1995 as the ‘common soil’ hypothesis. [5,6] The world health organization(WHO) first defined the syndrome in 1998 and called it the metabolic syndrome, a term that had been that had been used by Zimmet in 1991 to describe this cluster of findings. [7] The WHO criteria for the metabolic syndrome required the presence of diabetes mellitus (DM), impaired fasting glucose, impaired glucose tolerance (assessed by the euglycemia insulin clamp technique) plus two additional factors. [8] In 2001, the

national cholesterol education programme adult treatment panel III (NCEP ATP) simplified the definition to make it user-friendly for practitioners (Table 1). The NCEP ATPIII required any 3 of 5 risk factors, abnormal WC, High blood pressure and high fasting plasma glucose concentration. The NCEP ATPIII criteria were updated in 2005 to correspond with the new American Diabetes Association (ADA) standard of a normal fasting glucose level of less than 100 mg/dl. [9]

TABLE 1:-Comparison of WHO, NCEP ATPIII, and IDF Definitions of the metabolic syndrome*¹

Risk factors	WHO	NCEP ATPIII	IDF
	DM/IFG or IGT or IR plus any ≥2risk factors	Any ≥risk factors	Increased WC(ethnicity specific) plus any ≥2 riskfactors
Obesity	Waist to hip ration> 0.90 in men and >0.85 in women and BMI>30KG/m ²	WC≥102cm(40 in) in men or ≥88cm (35 in) in women	WC criteria dependent on ethnicity
Triglycerides	≥150mg/dl	≥150mg/dl	≥150mg/dl or drugs treatment for elevated level
HDL cholesterol	<35mg/dl in men and <39mg/dl in women	<40mg/dl in men and <50mg/dl in women	<40mg/dl in men and <50 mg/dl in women or drugs treatment for reduced level
Blood Pressure	≥140/90mm Hg	≥130 mm Hg systolic or ≥85mmHg diastolic	≥ 130mm Hg systolic or ≥85 mm Hg diastolic or drug treatment for hypertension
Fasting plasma glucose	IGT,IFG or type2 DM	≥110mg/dl	≥110 mg/dl or drug treatment for DM
Microalbuminuria	>30mg albumin/g creatinine		

The co-occurrence of any three of the abnormalities mentioned above metabolic syndrome.

Table 2: Additional metabolic criteria for research pro-inflammatory state 2006.

- *Elevated high sensitivity C-reactive protein
- *Elevated inflammatory cytokines (e.g. TNF-alpha, IL-6)
- *Decrease in adiponectin plasma levels
- Prothrombotic state
- *Fibrinolytic factors (PAI-1 etc.)
- *Clotting factors (fibrinogen etc.)
- Hormonal factors *Pituitary-adrenal axis

In 2009 Alberti et al presented a consensus criterion for the diagnosis of MS –the Joint Interim Statement (JIS) – that was endorsed by several societies, which chose the non-mandatory presence of any of the components, but the presence of at least three altered components in five and the WC measurement according to different ethnicities. Considering that the MS represents a higher risk for cardiovascular disease, DM, mobility alterations, cognitive

deficits and depression in the elderly, together with the scarcity of data in Brazil, this study aims at determining the prevalence of MS by four different diagnostic criteria and the agreement between them in a population older than 60 years old. [3]

PATHOPHYSIOLOGY

The current understanding of the pathogenesis of the metabolic syndrome suggest that multiple factors predispose to metabolic susceptibility for instance genetic defects in insulin signaling pathway, various disorders of adipose tissue, physical inactivity, mitochondrial dysfunction, polygenic variability in individual and certain ethnic groups, advancing age and certain drugs. The underlying pathophysiology of metabolic syndrome is a subject of debate.

Initial studies in this area suggest that insulin resistance has a primary role. [10-12]

Pathophysiological features of metabolic syndrome


Insulin

Insulin is a hormone produced by the beta cells of the islets of langerhans in the pancreas. [13] Once insulin is secreted into the portal venous system, 50% is degraded by the liver. Unexcreted insulin enter the systemic circulation and binds with receptors in target site. Its receptors stimulate intrinsic tyrosine kinase activity, leading to receptor autophosphorylation and the recruitment of intracellular signaling. These initiate a complex cascade of phosphorylation and dephosphorylation reaction, resulting in the widespread metabolic and mutogenic effects of insulin. [14] As an example, activation of the phosphatidylinositol-3-kinase (pi-3-kinase) pathway stimulates translocation of glucose

transporters (e.g., GLUT 4) to the cell surface, an event that is crucial for glucose uptake by skeletal muscle and fat. Activation of other insulin receptor signaling pathway induces glycogen synthesis, protein synthesis, lipogenesis, and regulation of various genes in insulin-responsive cells. [15]

Insulin resistance

Insulin resistance is defined as a decreased biological response to normal concentration of circulating insulin and is found in both obese, non-diabetic individuals and patients with type 2 diabetes. [14] It is a key feature of the metabolic syndrome and often progresses to type 2 diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. [16]



FIGER 1:-Pathophysiology of Insulin Resistance, Obesity and Hypertension

Hyperlipidemia

These lipid abnormalities primarily include hypertriglyceridemia and low High Density Lipoprotein cholesterol (HDL-C) and increased small dense low density lipoprotein (LDL). [15] Hyperlipidemia is a strong risk factor for cardiovascular disease.

Hyperlipidemia is referred to as elevated TG or cholesterol. [17] The problem can be due solely to hereditary factors, but more commonly it is an acquired condition. Increased risk for cardiovascular disease (CVD) is defined by risk factor. These include men with diabetes, having a family

history of heart disease in a close male relative younger than age 50 or a close female younger than age 60, a family history of high cholesterol, or personal history of multiple coronary disease risk factors. [17] Insulin plays an important role in the metabolism of free fatty acid by suppressing their release from adipose tissue, resulting in an increased concentration of plasma free fatty acids [18,19] Excess plasma free fatty acids lead to an increase flux of free fatty acid to liver resulting in an increase in hepatic triglyceride VLDL and cholesterol ester synthesis and secretion. [20,21] Also the lipoprotein excess plasma activity that is already impaired by insulin resistance leads to decreased catabolism of chylomicrons and VLDL. This reduced catabolic activity leads to decreased release of lipoprotein particles that are necessary components in the formation of HDL-cholesterol (HDL-C) [22,23] leading to low HDL-C levels. Other mechanisms for low HDL-C in patients with metabolic syndrome includes the altered or reduced activity of lecithin cholesterol acyltransferase (induced by the altered lipid fractions such as raised VLDL-C and increased triglycerides). [24,25] Therefore, hyperinsulinemia increases the production and decreases the metabolism of VLDL-C. Although it is not completely clear if isolated triglyceride elevations bear an independent risk for atherosclerosis. [26]

Obesity

Abdominal and central obesity is a major component of metabolic syndrome. Weight gain usually precedes development of the metabolic syndrome. [27] Central obesity and hyperinsulinemia may contribute to an increased risk of cardiovascular disease and stroke. [28] Central obesity is reflection of increased visceral fat, which is expected to have higher rate of flux of adipose tissue derived free fatty acid into the liver through the splanchnic circulation leading to increased very low-density lipoprotein production, hyperglyceridemia, increased glucose release from the liver into systemic

circulation and subsequent hyperinsulinemia, and insulin resistance.




FIGURE 2:- Central Obesity in Metabolic Syndrome (low HDL)

Coagulation markers

These coagulation markers abnormalities include elevated:- [29]

Plasminogen activator inhibitor-1 (PAI): PAI-1 has also been associated with CVD in experimental, clinical and epidemiological studies. Elevated plasma PAI-1 events such as angina pectoris, MI and restenosis after coronary angioplasty. [30]

Tissue plasminogen activator (t-PA): The t-PA antigen level increased in a stepwise fashion depending on the number of clinical characteristics associated with insulin resistance.

Factor 8, Von Willebrand factor (vWf): vWf and factor VIII level are positively associated with diabetes, BMI, waist to hip ratio, serum insulin and plasma triglycerides- all components of metabolic syndrome.

Factor 7, 9, 10 and Fibrinogen: These factors are also elevated in patients with metabolic syndrome and are also physiologically linked to microalbuminuria, an important component of metabolic syndrome. [31]

Blood pressure (BP)

Additionally, insulin resistance may lead to vasoconstriction, as insulin is a potent vasodilator. Three possible mechanisms by which increased blood pressure is associated with insulin resistance are:

1. High BP itself could cause insulin resistance
2. Insulin resistance could cause elevated BP
3. Both (elevated BP and insulin resistance) could be consequence of a common genetic trait. [31] It is still unclear by which mechanism insulin causes hypertension. [32]

However, it is well established that insulin itself has direct effects on the vasculature [33] and is a well-known dilator in various tissue in vivo, including vein [34] and brachial artery. [35] It has been suggested that the vasodilatory effect of insulin might contribute to increases in blood pressure. In addition, it has been experimentally shown that overall dyslipidemia could contribute to a chronic increase in vascular tone and consequently to hypertension. [36] Increasing evidence suggests a specific pathophysiology role of the renin angiotensin system (RAS) especially in patients with hypertension in accompaniment with the metabolic syndrome. [36] Plasma renin activity (PRA) is a powerful cardiovascular risk factor independently of other known risk factors [37] and clear associations between the RAS and metabolic cardiovascular risk factors has been shown. [38-40] Lind was able to confirm in untreated patients with essential hypertension that insulin resistance is related to elevated level of PRA when evaluated by the euglycaemic hyperinsulinaemic clamp. [41] However, the mechanisms connecting high PRA and insulin resistance are as yet unknown. In contrast, a causal association of insulin resistance and compensatory hyperinsulinemia with blood pressure elevation is established. Mechanisms involved in this relationship include insulin-mediated sodium retention, stimulation of the sympathetic nervous system, and promotion of vascular cell's growth or impairment of endothelial nitric oxide(NO) production in insulin-resistant states. [42] There are also accumulating evidence for an involvement of the endothelin system in the

development of hyperinsulinemia induced hypertension. [43]

Endothelin-1, which is considered to be the most powerful natural constrictor is the main effector of the endothelin system and mediates its effects via ET-A and ET-B receptor in the vasculature. [44] Although, vasoconstriction is its predominant action, ET-1 can also act on ET-B receptor present in endothelial cells in an autocrine fashion and promote production of ON and vasodilating prostaglandins. [45] Secondary hypertension, in contrast to essential hypertension, is not associated with insulin resistance which makes it less likely that high BP alone is a major cause of insulin resistance. It is plausible that insulin resistance could cause an elevation of BP given that hyperinsulinemia increases renal sodium and water reabsorption leading to extracellular volume expansion and an enhanced sympathetic activity. [46,47] Insulin resistance at a cellular level may lead to intracellular hypernatremia in view of the decreased potassium ion exchange. [48] Additionally, insulin resistance may lead to vasoconstriction, as insulin is a potent vasodilator. [49]

★ CONCLUSIONS

Life style modification remains the initial intervention of choice for this population. Modern lifestyle modification therapy combines specific recommendation on diet and exercise with behavioral strategies.

A realistic goal for overweight/obese persons is to reduce the body weight by less than 7% to 10% over a period of 6 to 12 months. Weight reduction should be combined with a daily minimum of 30 minutes of moderate-intensity physical activity.

Nutritional therapy calls for a low intake of saturated and total fat intake, reduced consumption of simple sugar and high glycemic index food and increase intakes of fruits, vegetables, legumes and whole grains.

Pharmacological treatment should be considered for those whose risk factors are not adequately reduced with lifestyle changes.

REFERENCES

1. Song SH, Hardisty CH. Diagnosing Metabolic syndrome in Type 2 Diabetics: does it matter QJM 2008; 101(6): 487-91
2. Falkner B, Hassink S, Ross J, Gidding S. Dysmetabolic syndrome: multiple risk factor premature adult disease in an adolescent girl. Pediatrics 2002; 110(pt1):e14
3. Maria A, Cardoso G, Martins W, Velarde L. Prevalence of Metabolic Syndrome in Elderly and Agreement among Four Diagnostic Criteria ABC 2014; 102(3):263-69
4. Himsworth HP. Diabetes mellitus. Its differentiation into insulin – sensitive and insulin- insensitive types. Lancet 1936: 5864-8
5. Jarrett RJ. Type 2 (non insulin dependent) diabetes mellitus and coronary heart disease: chicken, egg, or neither Diabetologia 1984; 26: 99-102
6. Sterl MP. Diabetes and cardiovascular disease: the ‘common soil’ hypothesis. Diabetes 1995;44:369-74
7. Johnson LW, Weinstock RS. The Metabolic Syndrome: Concepts and Controversy. Mayo Clin Proc 2006;81(12):1615-1620
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult. Executive summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel 111). JAMA 2001;285:2486-2497
9. Grundy SM et al. Diagnosis and management of the metabolic syndrome: an American heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005;112:2735-2752
10. Ferrannini E, Haffner S, Mitchell B, Stern M. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-422.
11. Ferrannini E, Buzzigoli G, Bonadonna R. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-357
12. Reaven G. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-131
13. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1495-1607.
14. Burtis CA, Ashwood ER, Bruns D. Tietz Textbook of clinical chemistry and Molecular sDiagnostics.2006;4:843,857
15. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison’s Principles of Internal Medicine.2005;16(11):2155
16. Adiels M, Olofsson S-O, Taskinen M-R, Boren J. Overproduction of Very Low-Density Lipoprotein Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology.2008;28:1225-1236
17. Fox KM, Wang L, Gandra SR, Quek RGW, Li L and Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. BMC Cardiovascular Disorders 2016; 16:13.
18. McKenney JM. Understanding and treating dyslipidemia associated with noninsulin dependent diabetes mellitus and hypertension. Pharmacotherapy 1993; 83:17-12B.
19. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83: 7B-12B
20. Sniderman AD, Scantlebury T, CianA one K. Hypertriglyceridemia hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Inten Med 2001;135:447-52
21. Reynisdottir S, Angelin B, Langin D et al. Adipose tissue lipoprotein lipase and hormone-sensitive lipase. Contrasting findings in familial combined hyperlipidemia and insulin resistance

- syndrome. *Arterioscler Thromb Vasc Biol* 1997;17:287-92
22. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. *Can J Cardiol* 2000;16:779-89
 23. Patsch JR, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. *Proc Natl Acad Sci USA* 1983;80:449-53
 24. Dieplinger H, Zechner R, Kostner GM. The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. *J Lipid Res* 1985;26:73-82
 25. Fielding CJ, Reaven GM, Fielding PE. Human noninsulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoadsorption of apolipoprotein E. *Proc Natl Acad Sci USA* 1982;79:365-69
 26. Ginsberg, H.N. Treatment for patients with the metabolic syndrome. *Am J Cardiol* 2003;91:29E-30
 27. Han TS, Williams K, Sattar N, Hunt KJ, Lean ME, Haffner SM. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome; San Antonio heart study. *Obes Res* 2002;10:23-31
 28. Berenson GS, Srinivasan SR. Emergence of obesity and cardiovascular risk for coronary artery disease: the Bogalusa Heart Study. *Prev Cardiol* 2001;4:16-121.
 29. Sower, J.R. et al. Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension* 2001;37:1053-1059
 30. Prabhakaran D and Anand SS. The metabolic syndrome: an emerging risk state for cardiovascular disease. *Circulation* 2003;108:420-25
 31. Prabhakaran D and Anand SS. The metabolic syndrome: an emerging risk state for cardiovascular disease. *Vasc Med* 2004;9(1):55-68
 32. McFarrlane SI et al. Mechanisms by which angiotensin-converting enzyme inhibitor prevent disease and cardiovascular disease. *Am J Cardiol* 2003;91:30H-37H.
 33. Govindarajan G et al. The cardiometabolic syndrome as a cardiovascular risk factor. *Am J Med Sci* 2005;330:311-318
 34. Baron AD. Insulin and the vasculature-old actors, new roles. *J Invest Med* 1996;44:406-412
 35. Morris RS et al. Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. *Fertil Steril* 1995;64:1099-1103
 36. Banos G et al. Vascular reactivity and effect of serum in a rat model of hypertriglyceridemia and hypertension. *Am J Hypertens* 1997;10:379-388
 37. Brunner HR et al. Essential hypertension: renin activity and aldosterone, heart attack and stroke. *N Engl J Med* 1972;286:441-449
 38. Allikmets K et al. Association between plasma renin activity and metabolic cardiovascular risk factor in essential hypertension. *J Intern Med* 1996;239:49-55.
 39. Goodfriend TL et al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. *Hypertension* 1995;25:30-36
 40. Phillips GB et al. Serum sex hormone levels and renin-sodium profile in men with hypertension. *Am J Hypertens* 1995;8:626-629
 41. Lind L et al. Insulin resistance in essential hypertension is related to plasma renin activity. *J Hum Hypertens* 1998;12:379-382
 42. Sartre C and Scherrer U. Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. *J Hypertens* 1999;17:1517-152
 43. Sarafidis PA and Barkris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? *J Clin Endocrinol Metab* 2007;92:379-385
 44. Luscher TF and Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. *Circulation* 2000;200:2434-2440
 45. Natali A, Quinones Galvan A, Arzilli F et al. Renovascular hypertension and insulin sensitivity. *Eur J Clin Invest* 1996;26:56-63

46. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. *Diabetes* 1981;30:19-25
47. Blaustein MP. Sodium ions, Calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. *Am J Physiol* 1977; 232:165-73
48. Canessa M, Brugnara C, Escobales N. The Li^+-Na^+ exchange and $\text{Na}^+-\text{K}^+-\text{CL}^-$ cotransport systems in essential hypertension. *Hypertension* 1987;10:14-10
49. Sower JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. *Hypertension* 1995;26(6 pts 1):869-79

How to cite this article: Devi R, Manhas S, Prasad S et al. Short review of metabolic syndrome. *International Journal of Research and Review*. 2017; 4(2):29-36.



International Journal of Research & Review (IJRR)

Publish your research work in this journal

The International Journal of Research & Review (IJRR) is a multidisciplinary indexed open access double-blind peer-reviewed international journal published by Galore Knowledge Publication Pvt. Ltd. This monthly journal is characterised by rapid publication of reviews, original research and case reports in all areas of research. The details of journal are available on its official website (www.gkpublication.in).

Submit your manuscript by email: gkpublication2014@gmail.com OR gkpublication2014@yahoo.com